Press Release: Ximedica Appoints Robert Brown Chief Executive Officer
Nov 13, 2018
Providence, RI (November 9, 2018) - Ximedica announced today that Robert Brown has been named Chief Executive Officer effective immediately. Randy Barko former CEO, will transition to a full time Executive Director role at Ximedica, effective August 1, 2018.
Robert joined Ximedica in February 2018, following over 20 years in the medical device industry. Robert most recently spent 11 years helping to build NxStage Medical into the global home hemodialysis leader, including his roles as CFO of NxStage Medical and President of NxStage Kidney Care. During this time, Robert helped grow the business dramatically, from its successful IPO until its pending sale to Fresenius.
Prior to NxStage, Robert spent a decade at Boston Scientific, including its multibillion dollar International business as its senior financial executive. Boston Scientific grew dramatically during this time as Robert oversaw compelling business expansion and 15 acquisition integrations, while holding several worldwide leadership positions. Robert previously worked for United Technologies and Deloitte & Touche, honing his financial and management skills and earned his MBA from the University of Michigan.
“Throughout his impressive career, Robert has a well-earned reputation for growing great teams, timely decision making, business effectiveness and passionate leadership,” said Paul LaViolette, Chairman of Ximedica’s Board of Directors. “We are extremely fortunate to have Robert’s diverse business and interpersonal skills at Ximedica.”
Randy will remain with Ximedica as Executive Director, maintaining his current position on the Ximedica Board of Directors while shifting his day-to-day focus exclusively toward business growth, customer development and expanding Ximedica’s presence in the device industry.
”I am appreciative for the opportunity to lead this exceptional organization of talented and dedicated professionals as they work to advance healthcare,” said Robert. “I am thankful for Randy’s past leadership and his commitment to continue pushing forward our aggressive growth plans. We look forward to an exciting next chapter at Ximedica.”
Ximedica is a full-service ISO 13485-certified and FDA-registered product development firm. For 30 years Ximedica has provided a unique growth platform enabling organizations to successfully deploy medical technology products into the market. Its headquarters are in Providence, R.I., with offices in Hong Kong, Minneapolis, San Francisco and Los Gatos. In November of 2014, SV LifeSciences, a Boston-based private equity firm, acquired a majority stake in Ximedica, enabling the company to execute its growth strategy. www.ximedica.com